Product Description: Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449.
CAS Number: 1044515-88-9
Molecular Weight: N/A
Compound Purity: 97.59
Research Area: Inflammation/Immunology
Solubility: H2O
Target: Interleukin Related